# Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations

**Authors:** Erkan Efe Okur, Emir Akdaşçi, Furkan Eker, Mikhael Bechelany, Sercan Karav

PMC · DOI: 10.3390/ph19020241 · 2026-01-30

## TL;DR

This review explores how silver nanoparticles can fight cancer by causing cell damage and death, but also highlights challenges like toxicity and the need for better targeting.

## Contribution

The paper provides a comprehensive overview of AgNPs' anticancer mechanisms and limitations, emphasizing recent advancements and strategies for clinical translation.

## Key findings

- AgNPs induce anticancer effects through oxidative stress, DNA damage, and apoptosis.
- Green-synthesized AgNPs show improved biocompatibility and selective toxicity to cancer cells.
- Strategies like surface functionalization and combination therapies are proposed to enhance efficacy and reduce toxicity.

## Abstract

Silver nanoparticles (AgNPs) have been studied extensively in recent years due to their biological activities. In addition to their well-known antibacterial, antioxidant, and anti-inflammatory properties, AgNPs also exhibit anticancer properties. Increasing evidence from in vivo and in vitro studies demonstrates that AgNPs exert significant anticancer effects through multiple mechanisms, including oxidative stress, mitochondrial dysfunction, DNA damage, cell cycle arrest, and apoptosis. In addition to these mechanisms, inhibition of certain pathways is also an important mechanism that enables AgNPs to exhibit anticancer activity. Furthermore, green-synthesized AgNPs often exhibit enhanced biocompatibility and improved selective cytotoxicity against cancer cells. Despite these promising findings, concerns regarding AgNP-associated toxicity, non-specific cellular damage, and long-term safety remain major challenges limiting their clinical translation. Strategies such as size and shape optimization, surface functionalization, and combination therapies have been recommended to enhance anticancer efficacy while minimizing adverse effects on healthy cells. This review brings together recent studies, offers a broad perspective, and aims to present an objective viewpoint to fully explain the anticancer potential and current challenges of AgNPs.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** SP1 (Sp1 transcription factor) [NCBI Gene 6667], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Slc31a1 (solute carrier family 31, member 1) [NCBI Gene 20529] {aka 4930445G01Rik, Ctr1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, DSG2 (desmoglein 2) [NCBI Gene 1829] {aka CDHF5, HDGC}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, CADM1 (cell adhesion molecule 1) [NCBI Gene 23705] {aka BL2, IGSF4, IGSF4A, NECL2, Necl-2, RA175}, TPSB2 (tryptase beta 2) [NCBI Gene 64499] {aka TPS2, tryptaseB, tryptaseC}, Ctla4 (cytotoxic T-lymphocyte-associated protein 4) [NCBI Gene 12477] {aka Cd152, Ctla-4, Ly-56}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, CAT (catalase) [NCBI Gene 847], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, NANOG (Nanog homeobox) [NCBI Gene 79923], PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, TSC1 (TSC complex subunit 1) [NCBI Gene 7248] {aka LAM, TSC}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, PTBP3 (polypyrimidine tract binding protein 3) [NCBI Gene 9991] {aka ROD1}, TAS2R64P (taste 2 receptor member 64, pseudogene) [NCBI Gene 338412] {aka PS2, T2R64, T2R64P}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CFLAR (CASP8 and FADD like apoptosis regulator) [NCBI Gene 8837] {aka CASH, CASP8AP1, CLARP, Casper, FLAME, FLAME-1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Atf6 (activating transcription factor 6) [NCBI Gene 226641] {aka 9130025P16Rik, 9630036G24, Atf6alpha, ESTM49}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, HULC (hepatocellular carcinoma up-regulated long non-coding RNA) [NCBI Gene 728655] {aka HCCAT1, LINC00078, NCRNA00078}, CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367] {aka A-152E5.1, ABCD-1, DC/B-CK, MDC, SCYA22, STCP-1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, MBP (myelin basic protein) [NCBI Gene 4155], CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577] {aka C-C, C-C-CKR-1, CD128, CD181, CDw128a, CKR-1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** death (MESH:D003643), Colon and Colorectal Cancer (MESH:D015179), K562 leukemia (MESH:D007938), metastasize (MESH:D009362), weight loss (MESH:D015431), Cytotoxic (MESH:D064420), infections (MESH:D007239), liver toxicity (MESH:D056486), T-cell leukemia (MESH:D015458), ovarian cancer (MESH:D010051), cardiac enlargement (MESH:D006331), Triple Negative Breast Cancer (MESH:D064726), Breast Cancer (MESH:D001943), organ damage (MESH:D000092124), glioblastoma (MESH:D005909), colon (MESH:D003108), neuropathy (MESH:D009422), breast, lung, prostate, and prostate cancer (MESH:D011472), brain cancer (MESH:D001932), liver cancer (MESH:D006528), MSI-H (MESH:D000848), intestinal toxicity (MESH:D007410), necrosis (MESH:D009336), pancreatic cancer (MESH:D010190), impaired mitochondrial function (MESH:D028361), inflammation (MESH:D007249), injury to (MESH:D014947), prostate cancer (MESH:D011471), microsatellite instability (MESH:D053842), Lung Cancer (MESH:D008175), Cancer (MESH:D009369), weakness (MESH:D018908), leukopenia (MESH:D007970), lung adenocarcinoma (MESH:D000077192), gastric adenocarcinoma (MESH:D013274), hair loss (MESH:D000505), organ dysfunctions (MESH:D009102), epidermoid carcinoma (MESH:D002294), SCID (MESH:D053632), impaired energy metabolism (MESH:D008659)
- **Chemicals:** proton (MESH:D011522), hexane (MESH:D006586), Adriamycin (MESH:D004317), epirubicin (MESH:D015251), H2O2 (MESH:D006861), N,N,N-trimethyl-(11-mercaptoundecyl) ammonium chloride (MESH:C538982), Cisplatin (MESH:D002945), AgC (-), superoxide (MESH:D013481), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), montmorillonite (MESH:D001546), Cyclopropane (MESH:C030797), fatty acids (MESH:D005227), MDA (MESH:D008315), Silanols (MESH:C082343), propolis (MESH:D011429), thiosemicarbazide (MESH:C005151), MTT (MESH:C070243), lipid (MESH:D008055), PLLA (MESH:C033616), ammonium hydroxide (MESH:D064753), polyphenol (MESH:D059808), ATP (MESH:D000255), ampicillin (MESH:D000667), glutamine (MESH:D005973), Citrate (MESH:D019343), GSH (MESH:D005978), flavonoid (MESH:D005419), ROS (MESH:D017382), folate (MESH:D005492), GEM (MESH:D000093542), EB (MESH:C478160), acetic acids (MESH:D000085), PI (MESH:D010716), CS (MESH:D048271), DHE (MESH:C067883), oxygen (MESH:D010100), zinc (MESH:D015032), trisodium citrate (MESH:C514290), Metal (MESH:D008670), gold (MESH:D006046), Siloxanes (MESH:D012833), DPPH (MESH:C004931), DPPC (MESH:D015060), GO (MESH:C000628730), tamoxifen (MESH:D013629), -lipoic acid (MESH:D008063), polysaccharides (MESH:D011134), NS (MESH:D009584), PTX (MESH:D017239), DCFH-DA (MESH:C029569), water (MESH:D014867), CCK-8 (MESH:D012844), hesperetin (MESH:C013015), Phosphonates (MESH:D063065), cholesterol (MESH:D002784), Mitoxantrone (MESH:D008942), ethanol (MESH:D000431), Hydroxyethyl cellulose (MESH:C002283), hydroxyl radical (MESH:D017665)
- **Species:** Curcuma aromatica (wild turmeric, species) [taxon 136209], Bacillus safensis (species) [taxon 561879], Danio rerio (leopard danio, species) [taxon 7955], Moringa oleifera (horseradish tree, species) [taxon 3735], Homo sapiens (human, species) [taxon 9606], Curcuma caesia (black zedoary, species) [taxon 508682], Staphylococcus aureus (species) [taxon 1280], Rattus norvegicus (brown rat, species) [taxon 10116], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Bifidobacterium animalis (species) [taxon 28025], Ducrosia anethifolia (species) [taxon 325716], Curcuma longa (turmeric, species) [taxon 136217], Cucurbita maxima (Boston marrow, species) [taxon 3661], Gallus gallus (bantam, species) [taxon 9031], Citrus maxima (buntan, species) [taxon 37334], Bacillus subtilis (species) [taxon 1423], Clitoria ternatea (species) [taxon 43366], Lacticaseibacillus rhamnosus (species) [taxon 47715], Eruca vesicaria subsp. sativa (arugula, subspecies) [taxon 29727], Taraxacum officinale (dandelion, species) [taxon 50225], Mus musculus (house mouse, species) [taxon 10090], Artemisia annua (sweet Annie, species) [taxon 35608], Metopion-like sp. (SA) (species) [taxon 188968], Shigella flexneri (species) [taxon 623], Lactobacillus acidophilus (species) [taxon 1579], Acorus calamus (Eurasian sweet-flag, species) [taxon 4465]
- **Cell lines:** Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), A2780cis — Homo sapiens (Human), Ovarian endometrioid adenocarcinoma, Cancer cell line (CVCL_1942), KAIMRC-2 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_B7K2), WI-38 — Homo sapiens (Human), Finite cell line (CVCL_0579), Mia-PaCa2 — Homo sapiens (Human), Pancreatic carcinoma, Cancer cell line (CVCL_4011), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MRC-5 — Homo sapiens (Human), Finite cell line (CVCL_0440), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), SKBR3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033), MCF-10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), Jurkat — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), HEK-293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), U-87 MG — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), A431 — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_0037), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), U251 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021), PANC-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480), LX-2 — Homo sapiens (Human), Transformed cell line (CVCL_5792), NIH/3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), A549 lung cancer — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_3008), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), A2780 — Homo sapiens (Human), Ovarian endometrioid adenocarcinoma, Cancer cell line (CVCL_0134), Vero kidney — Chlorocebus sabaeus (Green monkey), Spontaneously immortalized cell line (CVCL_0059), SK-OV-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), HOP-62 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1285), 32D — Mus musculus (Mouse), Factor-dependent cell line (CVCL_0118), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), MIA-PaCa2 — Homo sapiens (Human), Pancreatic undifferentiated carcinoma, Cancer cell line (CVCL_0428), CRL-4023 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_V021), A929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0462), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), MKN45 — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0434), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), hMSC — Homo sapiens (Human), Somatic stem cell (CVCL_Y509), PCS-800-011 — Homo sapiens (Human), Finite cell line (CVCL_1V10), HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), H1299 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0060), NCI-H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), LoVo — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0399), MOLT-4 — Homo sapiens (Human), Adult T acute lymphoblastic leukemia, Cancer cell line (CVCL_0013), A549 cancer — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_E025), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944222/full.md

---
Source: https://tomesphere.com/paper/PMC12944222